U.S. Expansion with Gel-One as a Growth Driver
First written in FY2016. 9 of 29 entries say "Restated". Latest entry: FY2026-H1.
Seikagaku moved to the "Worse" side of this theme in 2022.
0 other companies' latest entry also says "Other".
- FY2026-H1Gel-One increased, but U.S. pharmaceuticals diverged by productAnnual report
「Our sales declined 7.1% year on year, despite increases in Gel-One, a joint-function improver sold in the U.S., and China Alts, because of declines in Spartz FX, a joint-function improver sold in the U.S., and other products. The changes were mainly attributable to shipment timing.」
Although the company's sales of Gel-One increased, performance as a growth driver among U.S. pharmaceuticals diverged by product due to declines in Supartz FX and other products. - FY2025SoftenedAnnual report
「For Gel-One in the United States, local sales volumes declined. The company's sales also decreased year on year because the shipment timing for some products was pushed back to the next fiscal year.」
Local sales volumes of Gel-One, positioned as a growth driver, declined, and the company's sales also decreased due in part to shipments being pushed back. - FY2025-H1The company's sales increased despite declining or flat local salesAnnual report
「For Gel-One sold in the U.S., local sales volumes declined, but our sales increased year on year because of the rebound from lower shipments in the first quarter. For Spartz FX sold in the U.S., local sales volumes were similar to the prior-year period, but our sales increased because shipments had temporarily declined in the prior-year period.」
In the U.S. expansion of Gel-One, the growth driver, local sales volumes declined, while the company's sales increased due to the reversal of shipment timing effects. Local sales of Supartz FX were also broadly unchanged from the year-earlier period, but the company's sales increased. - FY2024-Q3Recovery after system change, but sales and revenue declinedAnnual report
「Although Gel-One, a single-injection joint-function improvement agent in the U.S., has been gradually recovering from the impact of the insurance reimbursement system change implemented in July 2022, local sales volumes and company sales declined.」
The U.S. expansion of Gel-One, the growth driver, showed signs of recovery from the impact of the system changes, but declines in local sales volumes and the company's sales continued. - FY2024-Q1SoftenedAnnual report
「Local sales volumes and company sales of Gel-One in the U.S. declined because of the change to the insurance reimbursement system implemented in July 2022.」
For Gel-One, positioned as a growth driver, local sales volumes and the company's sales declined due to the impact of changes to the reimbursement system, weakening the previous sales growth trend. - FY2023-Q2SoftenedAnnual report
「Local sales volumes of Gel-One in the U.S. declined because of the system change concerning price disclosure implemented from July 2022. Our sales increased substantially because of the effect of the weaker yen.」
For Gel-One, positioned as a growth driver, local sales volumes declined following a change in the price disclosure system, but the company's sales increased substantially due to the effect of the weaker yen. - FY2023-Q1SoftenedAnnual report
「Local sales volumes of Gel-One in the U.S. declined because of market trends ahead of the system change concerning price disclosure in July 2022 and the reaction to the increase in volumes as the market recovered from COVID-19 in the prior-year period. Our sales increased substantially because of higher shipment volumes due to shipment timing and the effect of the weaker yen.」
Local sales volumes of Gel-One in the United States declined, weakening the momentum of sales growth. However, the company's sales increased substantially due to shipment timing and the effect of the weaker yen. - FY2022-Q2RestatedAnnual report
「Local sales volumes and company sales of Gel-One in the U.S. increased, supported by the rebound from the market contraction caused by the spread of COVID-19 in the prior-year period and the success of the commercialization partner’s switching measures from competing products.」
The company continues to expand sales of Gel-One, positioned as a growth driver, through switching initiatives by its marketing partner. - FY2022-Q1AdvancedAnnual report
「Local sales volumes of Gel-One, a single-injection agent for improving joint function in the United States, increased substantially, benefiting from the reversal of the impact of postponed non-urgent medical procedures associated with the spread of COVID-19 in the year-earlier period and the success of measures to switch customers from competing products.」
For Gel-One, the growth driver, measures to switch customers from competing products proved effective, resulting in a substantial increase in local sales volumes. - FY2021RestatedAnnual report
「Although the U.S. market for Gel-One, a single-injection agent for improving joint function, declined sharply amid the postponement of non-urgent medical procedures and other effects of the spread of COVID-19, local sales volumes increased as the continued preference for products requiring fewer injections and the marketing partner's measures to switch customers from competing products proved effective.」
The company continues to report increases in Gel-One's local sales volumes in the United States, supported by the marketing partner's switching initiatives and preference for products requiring fewer injections. - FY2021-Q3RestatedAnnual report
「Gel-One, a single-injection joint-function improvement agent in the U.S., was significantly affected by the spread of COVID-19 in the first quarter, but local sales volumes increased from the second quarter onward as postponements of non-urgent medical procedures were eased. Our sales declined mainly because of the substantial impact of lower first-quarter shipments.」
The company continues to report that local sales volumes increased as postponements of medical procedures due to infectious disease eased, while lower first-quarter shipments affected its sales. - FY2021-Q2AdvancedAnnual report
「As postponements of non-urgent medical procedures in the U.S. were gradually eased, local sales volumes of Gel-One, a single-injection joint-function improvement agent, increased. Our sales declined because of the impact of lower shipments in the first quarter.」
Local sales volumes of Gel-One in the United States increased as postponements of medical procedures eased, but lower first-quarter shipments resulted in a smaller contribution to the company's sales. - FY2021-Q1SoftenedAnnual report
「Local sales volumes and company sales of Gel-One, a single-injection joint-function improvement agent in the U.S., declined because of urban lockdowns and postponements of non-urgent medical procedures resulting from the spread of COVID-19.」
In the U.S. expansion of Gel-One, the previously reported growth trend driven by the marketing partner's measures and preferred reimbursement was followed by declines in sales volumes and revenue due to postponements of medical procedures and other effects associated with the spread of infectious disease. - FY2020AdvancedAnnual report
「Local sales volumes and company sales of Gel-One, a single-injection joint-function improvement agent in the U.S., increased substantially as a result of obtaining preferred reimbursement from multiple insurers beginning in 2019 and measures by the commercialization partner to switch patients from competing products.」
In addition to the marketing partner's sales expansion efforts, progress in securing preferred reimbursement from multiple insurers and implementing measures to switch customers from competing products drove further growth in Gel-One's U.S. sales over the full fiscal year. - FY2020-Q3RestatedAnnual report
「In addition to obtaining preferred reimbursement from multiple insurers beginning in 2019, progress with measures to switch patients from competing products resulted in substantial increases in local sales volumes and company sales of Gel-One in the U.S.」
The company continues to expand sales of Gel-One in the United States, its growth driver, by securing preferred reimbursement and implementing measures to switch customers from competing products. - FY2020-Q2AdvancedAnnual report
「In addition to obtaining preferred reimbursement from multiple insurers beginning in 2019, measures to switch patients from competing products proved effective for Gel-One, a single-injection joint-function improvement agent in the U.S., resulting in substantial increases in local sales volumes and company sales.」
In the U.S. expansion of Gel-One, the company implemented measures to switch customers from competing products in addition to securing preferred reimbursement, resulting in substantial increases in sales volumes and revenue. - FY2020-Q1AdvancedAnnual report
「In addition to the commercialization partner’s sales expansion measures, Gel-One benefited from obtaining preferred reimbursement from multiple private insurers beginning in 2019, resulting in higher local sales volumes and company sales.」
In the U.S. expansion of Gel-One, progress in the sales environment, including gaining preferred reimbursement from multiple private insurers, led to increases in local sales volumes and the company's sales. - FY2019SoftenedAnnual report
「Local sales volumes of Gel-One, a single-injection joint-function improvement agent, increased steadily in the U.S., but the growth rate fell short of the target as market conditions became increasingly challenging.」
Unit growth from the marketing partner's sales expansion measures continued, but worsening market conditions caused the growth rate to fall short of the target. - FY2019-Q3SoftenedAnnual report
「Against this backdrop, local sales of Gel-One, a single-injection joint-function improvement agent, increased as a result of our commercialization partner’s sales expansion measures, but our sales declined because of lower local selling prices and a shift in shipment timing to the fourth quarter.」
Local sales increased as a result of the marketing partner's sales expansion measures, but the impact on the company's sales weakened due to lower unit prices and shipment timing shifts. - FY2019-Q2SoftenedAnnual report
「Local sales of Gel-One, a single-injection joint-function improvement agent, and our sales increased in the U.S., but their growth rates have gradually moderated.」
Although sales and revenue increased as a result of the U.S. expansion, the growth rate has gradually moderated. - FY2019-Q1Decrease in the company's sales due to shipment timing shiftsAnnual report
「Local sales of Gel-One, a single-injection joint-function improvement agent, increased in the U.S., but our sales declined because shipments were shifted to after the second quarter.」
Although local sales of Gel-One, the growth driver, increased, the company's sales decreased this quarter because shipments were shifted to periods after the second quarter. - FY2018-Q3AdvancedAnnual report
「Local sales volumes of Gel-One, a single-injection joint-function improvement agent, continued to increase in the U.S. Although local selling prices declined because of pricing measures for certain large customers, our sales increased due to higher shipments and the effect of the weaker yen.」
For Gel-One, positioned as a growth driver, the company reported increases in local sales volumes and its sales, despite lower selling prices resulting from pricing measures. - FY2018-Q2RestatedAnnual report
「Local sales volumes of Gel-One, a single-injection agent for improving joint function, continued to increase in the United States. Although the weaker yen had a positive effect, the company's sales were broadly unchanged from the year-earlier period due to the reversal of concentrated shipments associated with the product labeling change in the year-earlier period and the impact of lower local selling prices resulting from pricing measures for certain major customers.」
Although the increase in Gel-One's local sales volumes in the United States continued, the company's sales were broadly unchanged from the year-earlier period due to the reversal of concentrated shipments associated with the prior year's labeling change and pricing measures for certain major customers. - FY2018-Q1RestatedAnnual report
「Although local sales volumes of Gel-One, a single-injection agent for improving joint function, continued to increase in the United States, the company's sales rose only slightly due to the impact of concentrated shipments in the year-earlier period associated with a product labeling change.」
The company continues to report increases in Gel-One's local sales volumes in the United States. However, growth in the company's sales was limited by concentrated shipments in the year-earlier period. - FY2017RestatedAnnual report
「Local sales volumes of Gel-One, a single-injection agent for improving joint function in the United States and a designated growth driver, have steadily increased as a result of market development efforts by its marketing partner, Zimmer Biomet.」
The company continues to pursue its policy of expanding U.S. sales of Gel-One, positioned as a growth driver, through market development by its marketing partner. - FY2017-Q3RestatedAnnual report
「In the United States, local sales of Gel-One, a single-injection agent for improving joint function, remained firm as the company focused on supporting its marketing partner's activities. The company's sales also increased, more than offsetting the impact of the stronger yen.」
The company continues to pursue U.S. expansion and sales growth for Gel-One by supporting the activities of its marketing partner. - FY2017-Q2RestatedAnnual report
「The company will continue to focus on supporting the activities of its marketing partner and aim to further expand sales.」
The company continues to support its marketing partner's activities and pursue sales growth for Gel-One in the United States. - FY2017-Q1AdvancedAnnual report
「The company will continue to focus on supporting the activities of its marketing partner and aim to further expand sales.」
Local sales of Gel-One increased as the marketing partner expanded its sales organization, and the company continues to support its activities. - FY2016First statedAnnual report
「The company will promote growth in U.S. sales of Gel-One, its growth driver, and expand into new markets.」
The company has indicated a policy of supporting the sales activities of its marketing partner and implementing further measures to raise product awareness.